This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): AbGn-7, AbGn107
Description: AbGn-7 is an antibody drug conjugate with a fully owned first-in-class linker-payload, with an undisclosed molecular target, but one that binds to about 50% of pancreatic and stomach tumors. The antibody is believed to kill epitope positive pancreatic and stomach tumor cells through apoptosis, complement-dependent cytotoxicity (CDC), and antibody-dependent cell-mediated cytotoxicity (ADCC).
Pink Sheet Weekly Trademark Review Jan. 10, 2017
Additional information available to subscribers only: